A record of what Citi Analysis said publicly, with the source. Not advice.
Pending — not yet graded
“Divi's Laboratories remains Citi's top pharma pick, with an expectation of 15% more upside. The company's strong position in the API and custom synthesis segments, coupled with a robust order book, underpins this positive outlook.”
Citi Analysis’s track record (trackable calls only): 53 graded calls · 95% CI 40–66%
Divi's LaboratoriesBullishCalled 29 Nov 2024
This call has no verdict yet — it is graded HIT or MISS against real price data once a close decides it. Save it above to find it again from your profile.
Read the original articleSee Citi Analysis’s full track record